{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T10:52:46Z","timestamp":1783075966828,"version":"3.54.6"},"reference-count":189,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2009,7,1]],"date-time":"2009-07-01T00:00:00Z","timestamp":1246406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Research in Developmental Disabilities"],"published-print":{"date-parts":[[2009,7]]},"DOI":"10.1016\/j.ridd.2008.10.010","type":"journal-article","created":{"date-parts":[[2008,12,12]],"date-time":"2008-12-12T11:25:41Z","timestamp":1229081141000},"page":"613-669","source":"Crossref","is-referenced-by-count":59,"title":["Practical guidelines for the use of new generation antipsychotic drugs (except clozapine) in adult individuals with intellectual disabilities"],"prefix":"10.1016","volume":"30","author":[{"given":"Jose","family":"de Leon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Greenlee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Barber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Sabaawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nirbhay N.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ridd.2008.10.010_bib1","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1176\/ajp.156.11.1686","article-title":"Antipsychotic-induced weight gain: A comprehensive research synthesis","volume":"156","author":"Allison","year":"1999","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.ridd.2008.10.010_bib2","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.biopsych.2006.09.023","article-title":"Seizure incidence in psychopharmacological clinical trials: An analysis of Food and Drug Administration (FDA) summary basis of approval reports","volume":"62","author":"Alper","year":"2007","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.ridd.2008.10.010_bib3","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/(SICI)1098-2779(1999)5:4<253::AID-MRDD2>3.0.CO;2-R","article-title":"Atypical antipsychotics in persons with developmental disabilities","volume":"5","author":"Aman","year":"1999","journal-title":"Mental Retardation and Developmental Disabilities Research Reviews"},{"key":"10.1016\/j.ridd.2008.10.010_bib4","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.4088\/JCP.v65n0907","article-title":"Treatment of behavior disorders in mental retardation: Report on transitioning to atypical antipsychotics, with an emphasis on risperidone","volume":"65","author":"Aman","year":"2004","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1016\/j.ridd.2008.10.010_bib5","doi-asserted-by":"crossref","first-page":"596","DOI":"10.2337\/diacare.27.2.596","article-title":"Consensus development conference on antipsychotic drugs and obesity and diabetes","volume":"27","author":"American Diabetes Association (ADA)","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ridd.2008.10.010_bib6","doi-asserted-by":"crossref","first-page":"464","DOI":"10.4088\/JCP.v65n0403","article-title":"Neuroleptic malignant syndrome and atypical antipsychotic drugs","volume":"65","author":"Ananth","year":"2004","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1016\/j.ridd.2008.10.010_bib7","unstructured":"Anderson, C. B., True, J. E., Ereshefsky, L., Miller, A. L., Peters, B. L., & Velligan, D. I. (1993, May). Risperidone dose, plasma levels and response (NR 217, p. 113). San Francisco, CA: 1993 New Research Program and Abstracts, American Psychiatric Association Annual Meeting."},{"key":"10.1016\/j.ridd.2008.10.010_bib8","doi-asserted-by":"crossref","first-page":"989","DOI":"10.2165\/00003088-200544100-00001","article-title":"Pregnancy-induced changes in pharmacokinetics: A mechanistic-based approach","volume":"44","author":"Anderson","year":"2005","journal-title":"Clinical Pharmacokinetics"},{"key":"10.1016\/j.ridd.2008.10.010_bib9","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1176\/appi.psy.44.3.255","article-title":"Six patterns of drug\u2013drug interactions","volume":"44","author":"Armstrong","year":"2003","journal-title":"Psychosomatics"},{"key":"10.1016\/j.ridd.2008.10.010_bib10","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/sj.mp.4002009","article-title":"Pharmacogenetics and pharmacogenomics of schizophrenia: A review of last decade of research","volume":"12","author":"Arranz","year":"2007","journal-title":"Molecular Psychiatry"},{"key":"10.1016\/j.ridd.2008.10.010_bib11","series-title":"Seroquel (quetiapine fumarate tablets) package insert","author":"Astra Zeneca","year":"2007"},{"key":"10.1016\/j.ridd.2008.10.010_bib12","series-title":"Seroquel XR (quetiapine fumarate extended release tablets) package insert","author":"Astra Zeneca","year":"2007"},{"key":"10.1016\/j.ridd.2008.10.010_bib13","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1002\/pds.1496","article-title":"Mortality in schizophrenia","volume":"16","author":"Auquier","year":"2007","journal-title":"Pharmacoepidemiology and Drug Safety"},{"key":"10.1016\/j.ridd.2008.10.010_bib14","doi-asserted-by":"crossref","first-page":"935","DOI":"10.2165\/00023210-200519110-00004","article-title":"Head-to-head comparison of the costs of atypical antipsychotics: A systematic review","volume":"19","author":"Barbui","year":"2005","journal-title":"CNS Drugs"},{"key":"10.1016\/j.ridd.2008.10.010_bib15","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1177\/026988110201600113","article-title":"A systematic review of the use of atypical antipsychotics in autism","volume":"16","author":"Barnard","year":"2002","journal-title":"Journal of Psychopharmacology"},{"key":"10.1016\/j.ridd.2008.10.010_bib16","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1176\/appi.ajp.163.3.555","article-title":"The CATIE study [Letter]","volume":"163","author":"Basil","year":"2006","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.ridd.2008.10.010_bib17","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1055\/s-2004-832687","article-title":"The AGNP-TDM expert group consensus guidelines: Therapeutic drug monitoring in psychiatry","volume":"37","author":"Baumann","year":"2004","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.ridd.2008.10.010_bib18","doi-asserted-by":"crossref","first-page":"763","DOI":"10.2165\/00003088-200443120-00001","article-title":"Pharmacokinetic interactions of topiramate","volume":"43","author":"Bialer","year":"2004","journal-title":"Clinical Pharmacokinetics"},{"key":"10.1016\/j.ridd.2008.10.010_bib19","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.4088\/JCP.v63n1116g","article-title":"High degree of tolerability for monotherapy with high doses of quetiapine: A case report","volume":"63","author":"Bobes","year":"2002","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1016\/j.ridd.2008.10.010_bib20","first-page":"118","article-title":"Dyskinetic movement disorder among adults with mental retardation: Phenomenology and co-occurrence with stereotypy","volume":"101","author":"Bodfish","year":"1996","journal-title":"American Journal on Mental Retardation"},{"key":"10.1016\/j.ridd.2008.10.010_bib21","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/j.pnpbp.2008.04.018","article-title":"Estimating the effects of co-medications on plasma olanzapine concentrations by using a mixed model","volume":"32","author":"Botts","year":"2008","journal-title":"Progress in Neuro-Psychopharmacology & Biological Psychiatry"},{"key":"10.1016\/j.ridd.2008.10.010_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1081\/CLT-100102873","article-title":"The pharmacology and toxicology of atypical antipsychotic agents","volume":"39","author":"Burns","year":"2001","journal-title":"Journal of Toxicology. Clinical Toxicology"},{"key":"10.1016\/j.ridd.2008.10.010_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S1461145700001760","article-title":"Overdose profiles of new antipsychotic agents","volume":"3","author":"Capel","year":"2000","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"10.1016\/j.ridd.2008.10.010_bib24","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1089\/cap.2004.14.372","article-title":"Second-generation antipsychotic medications in children and adolescents","volume":"14","author":"Cheng-Shannon","year":"2004","journal-title":"Journal of Child and Adolescent Psychopharmacology"},{"key":"10.1016\/j.ridd.2008.10.010_bib25","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.schres.2006.07.011","article-title":"A model of anticholinergic activity of atypical antipsychotic medications","volume":"88","author":"Chew","year":"2006","journal-title":"Schizophrenia Research"},{"key":"10.1016\/j.ridd.2008.10.010_bib26","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.4088\/JCP.v66n1203","article-title":"Dosing of quetiapine in schizophrenia: How clinical practice differs from registration studies","volume":"66","author":"Citrome","year":"2005","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1016\/j.ridd.2008.10.010_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1210\/er.2001-0036","article-title":"The role of prolactin in mammary carcinoma","volume":"24","author":"Clevenger","year":"2003","journal-title":"Endocrine Reviews"},{"issue":"Suppl. 9","key":"10.1016\/j.ridd.2008.10.010_bib28","first-page":"4","article-title":"Treatment of bipolar disorder during pregnancy","volume":"68","author":"Cohen","year":"2007","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1016\/j.ridd.2008.10.010_bib29","doi-asserted-by":"crossref","first-page":"60","DOI":"10.4088\/JCP.v64n0112","article-title":"Weight, lipids, glucose, and behavioral measures with ziprasidone treatment in a population with mental retardation","volume":"64","author":"Cohen","year":"2003","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1016\/j.ridd.2008.10.010_bib30","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1177\/070674370605100804","article-title":"Metabolic monitoring for patients treated with antipsychotic medications","volume":"51","author":"Cohn","year":"2006","journal-title":"Canadian Journal of Psychiatry"},{"key":"10.1016\/j.ridd.2008.10.010_bib31","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1089\/cap.2006.0117","article-title":"One-year incidence rates of tardive dyskinesia in children and adolescents treated with second-generation antipsychotics: A systematic review","volume":"17","author":"Correll","year":"2007","journal-title":"Journal of Child and Adolescent Psychopharmacology"},{"key":"10.1016\/j.ridd.2008.10.010_bib32","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1176\/appi.ajp.161.3.414","article-title":"Lower risk for tardive dyskinesia associated with second-generation antipsychotics: A systematic review of 1-year studies","volume":"161","author":"Correll","year":"2004","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.ridd.2008.10.010_bib33","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0306-4530(02)00113-0","article-title":"Sexual dysfunction and antipsychotic treatment","volume":"28","author":"Cutler","year":"2003","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.ridd.2008.10.010_bib34","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1097\/01.ftd.0000211800.66569.c9","article-title":"Determination of olanzapine in human plasma by reversed-phase high-performance liquid chromatography with ultraviolet detection","volume":"28","author":"D\u2019Arrigo","year":"2006","journal-title":"Therapeutic Drug Monitoring"},{"key":"10.1016\/j.ridd.2008.10.010_bib35","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1176\/appi.ps.55.5.491","article-title":"Psychopharmacology: Atypical antipsychotic dosing: The effect of smoking and caffeine","volume":"55","author":"de Leon","year":"2004","journal-title":"Psychiatric Service"},{"key":"10.1016\/j.ridd.2008.10.010_bib36","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1176\/appi.ps.55.2.125","article-title":"Psychopharmacology: Atypical antipsychotic dosing: The effect of co-medication with anticonvulsants","volume":"55","author":"de Leon","year":"2004","journal-title":"Psychiatric Services"},{"key":"10.1016\/j.ridd.2008.10.010_bib37","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1586\/14737159.6.3.277","article-title":"The AmpliChip CYP450 Test: Personalized medicine has arrived in psychiatry","volume":"6","author":"de Leon","year":"2006","journal-title":"Expert Review of Molecular Diagnostics"},{"key":"10.1016\/j.ridd.2008.10.010_bib38","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s00406-006-0705-z","article-title":"The effect of atypical versus typical antipsychotics on tardive dyskinesia: A naturalistic study","volume":"257","author":"de Leon","year":"2007","journal-title":"European Archives of Psychiatry and Clinical Neurosciences"},{"key":"10.1016\/j.ridd.2008.10.010_bib39","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/JCP.0b013e318166f533","article-title":"Beyond the \u201chype\u201d on the association between metabolic syndrome and atypical antipsychotics: The confounding effects of cohort, typical antipsychotics, severe mental illness, and co-morbid substance use (editorial)","volume":"28","author":"de Leon","year":"2008","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1016\/j.ridd.2008.10.010_bib40","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1176\/appi.psy.46.3.262","article-title":"The dosing of atypical antipsychotics","volume":"46","author":"de Leon","year":"2005","journal-title":"Psychosomatics"},{"key":"10.1016\/j.ridd.2008.10.010_bib41","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.schres.2007.05.020","article-title":"Planning for the optimal design of studies to personalize antipsychotic prescriptions in the post-CATIE era: The clinical and pharmacoepidemiological data suggest that pursuing the pharmacogenetics of metabolic syndrome complications (hypertension, diabetes mellitus and hyperlipidemia) may be a reasonable strategy","volume":"96","author":"de Leon","year":"2007","journal-title":"Schizophrenia Research"},{"key":"10.1016\/j.ridd.2008.10.010_bib42","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1176\/appi.psy.49.4.347","article-title":"A preliminary attempt to personalize risperidone dosing using drug-drug interactions and genetics. Part II","volume":"49","author":"de Leon","year":"2008","journal-title":"Psychosomatics"},{"key":"10.1016\/j.ridd.2008.10.010_bib43","first-page":"119","article-title":"Anticholinergics to treat clozapine withdrawal [Letter]","volume":"55","author":"de Leon","year":"1994","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1016\/j.ridd.2008.10.010_bib44","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/BF03256453","article-title":"The AmpliChip CYP450 Genotyping Test: Integrating a new clinical tool","volume":"10","author":"de Leon","year":"2006","journal-title":"Molecular Diagnosis and Therapy"},{"key":"10.1016\/j.ridd.2008.10.010_bib45","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4088\/JCP.v66n0103","article-title":"CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation","volume":"66","author":"de Leon","year":"2005","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1016\/j.ridd.2008.10.010_bib46","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1055\/s-2007-973836","article-title":"A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels","volume":"40","author":"de Leon","year":"2007","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.ridd.2008.10.010_bib47","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1046\/j.1365-2710.1999.00218.x","article-title":"Clozapine-olanzapine: A potentially dangerous switch. A report of two cases","volume":"24","author":"Delassus-Guenault","year":"1999","journal-title":"Journal of Clinical Pharmacy and Therapeutics"},{"key":"10.1016\/j.ridd.2008.10.010_bib48","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1345\/aph.1E054","article-title":"Thyroid function alterations following quetiapine initiation in a developmentally disabled adolescent","volume":"38","author":"Dobbs","year":"2004","journal-title":"Annals of Pharmacotherapy"},{"key":"10.1016\/j.ridd.2008.10.010_bib49","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/S0006-3223(03)00170-7","article-title":"Incidence of tardive dyskinesia with typical versus atypical antipsychotics in very high risk patients","volume":"53","author":"Dolder","year":"2003","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.ridd.2008.10.010_bib50","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/01.mop.0000151714.87702.a9","article-title":"Toxicology and overdose of atypical antipsychotic medications in children: Does newer necessarily mean safer?","volume":"17","author":"Dubois","year":"2005","journal-title":"Current Opinion in Pediatrics"},{"key":"10.1016\/j.ridd.2008.10.010_bib51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jhealeco.2004.08.001","article-title":"Do new prescription drugs pay for themselves? The case of second-generation antipsychotics","volume":"24","author":"Duggan","year":"2005","journal-title":"Journal of Health Economics"},{"key":"10.1016\/j.ridd.2008.10.010_bib52","first-page":"14","article-title":"Generic Zyprexa in Canada attracting US sz consumers","author":"Editor","year":"2008","journal-title":"Schizophrenia Digest"},{"key":"10.1016\/j.ridd.2008.10.010_bib53","series-title":"ZyprexaR Olanzapine tablets, ZyprexaR ZydisR Olanzapine orally disintegrating tablets, ZyprexaR Intramuscular olanzapine for injection","author":"Eli Lilly Company","year":"2007"},{"key":"10.1016\/j.ridd.2008.10.010_bib54","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1177\/070674370605100805","article-title":"Pharmacologic and nonpharmacologic strategies for weight gain and metabolic disturbance in patients treated with antipsychotic medications","volume":"51","author":"Faulkner","year":"2006","journal-title":"Canadian Journal of Psychiatry"},{"issue":"Suppl. 11","key":"10.1016\/j.ridd.2008.10.010_bib55","first-page":"37","article-title":"Weight gain and antidepressants","volume":"61","author":"Fava","year":"2000","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1016\/j.ridd.2008.10.010_bib56","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/0895-4356(96)00040-6","article-title":"Twentieth century paradigms that threaten both scientific and humane medicine in the twenty-first century","volume":"49","author":"Feinstein","year":"1996","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1016\/j.ridd.2008.10.010_bib57","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0002-9343(97)00244-1","article-title":"Problems in the \u201cEvidence\u201d of \u201cEvidence-based medicine\u201d","volume":"103","author":"Feinstein","year":"1997","journal-title":"American Journal of Medicine"},{"key":"10.1016\/j.ridd.2008.10.010_bib58","doi-asserted-by":"crossref","first-page":"643","DOI":"10.2165\/00002018-200326090-00004","article-title":"Treatment of psychosis in Parkinson's disease: Safety considerations","volume":"26","author":"Fernandez","year":"2003","journal-title":"Drug Safety"},{"key":"10.1016\/j.ridd.2008.10.010_bib59","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1592\/phco.22.16.1500.33697","article-title":"Elevation of carbamazepine-10,11-epoxide by quetiapine","volume":"22","author":"Fitzgerald","year":"2002","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ridd.2008.10.010_bib60","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.ajo.2004.05.038","article-title":"Twice-yearly exams unnecessary for patients taking quetiapine","volume":"138","author":"Fraunfelder","year":"2004","journal-title":"American Journal of Ophthalmology"},{"key":"10.1016\/j.ridd.2008.10.010_bib61","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1176\/ajp.2006.163.12.2029","article-title":"The costs of drugs for schizophrenia","volume":"163","author":"Freedman","year":"2006","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.ridd.2008.10.010_bib62","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1177\/070674370104600807","article-title":"Atypical antipsychotic use in treating adolescents and young adults with developmental disabilities","volume":"46","author":"Friedlander","year":"2001","journal-title":"Canadian Journal of Psychiatry"},{"key":"10.1016\/j.ridd.2008.10.010_bib63","doi-asserted-by":"crossref","first-page":"433","DOI":"10.18553\/jmcp.2004.10.5.433","article-title":"Current status of prospective drug utilization review","volume":"10","author":"Fulda","year":"2004","journal-title":"Journal of Managed Care Pharmacy"},{"key":"10.1016\/j.ridd.2008.10.010_bib64","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/00007691-200302000-00007","article-title":"Therapeutic drug monitoring of olanzapine: The combined effect of age, gender, smoking, and comedication","volume":"25","author":"Gex-Fabry","year":"2003","journal-title":"Therapeutic Drug Monitoring"},{"key":"10.1016\/j.ridd.2008.10.010_bib65","doi-asserted-by":"crossref","first-page":"421","DOI":"10.3928\/0048-5713-20000601-05","article-title":"Use of psychotropic medication during pregnancy: Risk management guidelines","volume":"30","author":"Gold","year":"2000","journal-title":"Psychiatric Annals"},{"key":"10.1016\/j.ridd.2008.10.010_bib66","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1592\/phco.2005.25.11.1660","article-title":"Ziprasidone overdose: Cases recorded in the database of Pfizer-Spain and literature review","volume":"25","author":"G\u00f3mez-Criado","year":"2005","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ridd.2008.10.010_bib67","doi-asserted-by":"crossref","first-page":"325","DOI":"10.2165\/00023210-199809040-00007","article-title":"Quetiapine: A review of its use in schizophrenia","volume":"9","author":"Gunasekara","year":"1998","journal-title":"CNS Drugs"},{"key":"10.1016\/j.ridd.2008.10.010_bib68","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.2165\/00003495-200262080-00015","article-title":"Ziprasidone: A review of its use in schizophrenia and schizoaffective disorders","volume":"62","author":"Gunasekara","year":"2002","journal-title":"Drugs"},{"key":"10.1016\/j.ridd.2008.10.010_bib69","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.2165\/00003495-200464200-00003","article-title":"Antipsychotic-induced hyperprolactinaemia: Mechanisms, clinical features and management","volume":"64","author":"Haddad","year":"2004","journal-title":"Drugs"},{"key":"10.1016\/j.ridd.2008.10.010_bib70","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2165\/00023210-200620040-00003","article-title":"The SOHO (Schizophrenia Outpatient Health Outcome) study: Implications for the treatment of schizophrenia","volume":"20","author":"Haro","year":"2006","journal-title":"CNS Drugs"},{"key":"10.1016\/j.ridd.2008.10.010_bib71","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/01.jcp.0000104913.75206.62","article-title":"A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition","volume":"24","author":"Harrigan","year":"2004","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1016\/j.ridd.2008.10.010_bib72","first-page":"91","article-title":"Antipsychotic medications and sudden cardiac death","volume":"36","author":"Harrison","year":"2002","journal-title":"Psychopharmacology Bulletin"},{"key":"10.1016\/j.ridd.2008.10.010_bib73","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.2165\/00003495-200464150-00010","article-title":"Aripiprazole: A review of its use in schizophrenia and schizoaffective disorders","volume":"64","author":"Harrison","year":"2004","journal-title":"Drugs"},{"key":"10.1016\/j.ridd.2008.10.010_bib74","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s10803-006-0078-1","article-title":"A crossover study of risperidone in children, adolescents and adults with mental retardation","volume":"36","author":"Hellings","year":"2006","journal-title":"Journal of Autism and Developmental Disorders"},{"key":"10.1016\/j.ridd.2008.10.010_bib75","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2165\/00023210-200216020-00001","article-title":"Atypical antipsychotic-induced diabetes mellitus: How strong is the evidence?","volume":"16","author":"Henderson","year":"2002","journal-title":"CNS Drugs"},{"key":"10.1016\/j.ridd.2008.10.010_bib76","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1055\/s-2006-946701","article-title":"The complexity of active metabolites in therapeutic drug monitoring of psychotropic drugs","volume":"39","author":"Hendset","year":"2006","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.ridd.2008.10.010_bib77","doi-asserted-by":"crossref","first-page":"833","DOI":"10.2165\/00002018-200629100-00002","article-title":"Atypical antipsychotics for neuropsychiatric symptoms of dementia: Malignant or maligned?","volume":"29","author":"Herrmann","year":"2006","journal-title":"Drug Safety"},{"key":"10.1016\/j.ridd.2008.10.010_bib78","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/00007691-200404000-00012","article-title":"Therapeutic monitoring of new antipsychotic drugs","volume":"26","author":"Hiemke","year":"2004","journal-title":"Therapeutic Drug Monitoring"},{"key":"10.1016\/j.ridd.2008.10.010_bib79","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1517\/17425255.3.4.557","article-title":"Alterations in drug disposition during pregnancy: Implications for drug therapy","volume":"3","author":"Hodge","year":"2007","journal-title":"Expert Opinion on Drug Metabolism & Toxicology"},{"key":"10.1016\/j.ridd.2008.10.010_bib80","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/S0140-6736(03)14236-5","article-title":"Targeted treatments for symptom domains in child and adolescent autism","volume":"362","author":"Hollander","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ridd.2008.10.010_bib81","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1136\/jme.21.5.259","article-title":"Evidence based medicine and ethics","volume":"21","author":"Hope","year":"1995","journal-title":"Journal of Medical Ethics"},{"key":"10.1016\/j.ridd.2008.10.010_bib82","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1176\/appi.ajp.162.9.1755-a","article-title":"Intravenous quetiapine abuse","volume":"162","author":"Hussain","year":"2005","journal-title":"American Journal of Psychiatry"},{"issue":"9 Suppl. 14","key":"10.1016\/j.ridd.2008.10.010_bib83","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S1092852900026201","article-title":"Akathisia: Problem of history or concern of today.","volume":"12","author":"Iqbal","year":"2007","journal-title":"CNS Spectrums"},{"key":"10.1016\/j.ridd.2008.10.010_bib84","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.4088\/JCP.v64n1018","article-title":"Olanzapine for self-injurious, aggressive, and disruptive behaviors in intellectually disabled adults: A retrospective, open-label, naturalistic trial","volume":"64","author":"Janowsky","year":"2003","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1016\/j.ridd.2008.10.010_bib85","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.4088\/JCP.v67n0815","article-title":"Relapse of aggressive and disruptive behavior in mentally retarded adults following antipsychotic drug withdrawal predicts psychotropic drug use a decade later","volume":"67","author":"Janowsky","year":"2006","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1016\/j.ridd.2008.10.010_bib86","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/01.jcp.0000150218.51433.7b","article-title":"Minimally effective doses of conventional antipsychotic medications used to treat aggression, self-injurious and destructive behaviors in mentally retarded adults","volume":"25","author":"Janowsky","year":"2005","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1016\/j.ridd.2008.10.010_bib87","series-title":"Invega\u2122 Extended-release tablets package insert","author":"Janssen","year":"2007"},{"key":"10.1016\/j.ridd.2008.10.010_bib88","series-title":"RisperdalR (risperidone) tablets\/oral solution. RisperdalR M-TabR (risperidone) orally disintegrating tablets","author":"Janssen","year":"2007"},{"key":"10.1016\/j.ridd.2008.10.010_bib89","series-title":"RisperdalR ConstaR (risperidone) long-acting injection","author":"Janssen","year":"2007"},{"key":"10.1016\/j.ridd.2008.10.010_bib90","series-title":"Evidence-based practice: Logic and critical thinking in medicine","author":"Jenicek","year":"2005"},{"key":"10.1016\/j.ridd.2008.10.010_bib91","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1176\/appi.ajp.2007.06101710","article-title":"Mortality risk in patients with dementia treated with antipsychotics versus other psychiatric medications","volume":"164","author":"Kales","year":"2007","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.ridd.2008.10.010_bib92","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.schres.2006.09.012","article-title":"Treatment of schizophrenia with paliperidone extended-release tablets: A 6-week placebo-controlled trial","volume":"90","author":"Kane","year":"2007","journal-title":"Schizophrenia Research"},{"key":"10.1016\/j.ridd.2008.10.010_bib93","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1176\/ajp.2006.163.8.1316","article-title":"Tardive dyskinesia circa 2006","volume":"163","author":"Kane","year":"2006","journal-title":"American Journal of Psychiatry"},{"issue":"12 Suppl.","key":"10.1016\/j.ridd.2008.10.010_bib94","doi-asserted-by":"crossref","first-page":"S272","DOI":"10.1111\/j.1532-5415.2004.52604.x","article-title":"Optimizing atypical antipsychotic treatment strategies in the elderly","volume":"52","author":"Katz","year":"2004","journal-title":"Journal of American Geriatrics Society"},{"key":"10.1016\/j.ridd.2008.10.010_bib95","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1176\/appi.ajp.162.5.1020","article-title":"Quetiapine discontinuation syndrome [Letter]","volume":"162","author":"Kim","year":"2005","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.ridd.2008.10.010_bib96","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/BF02849966","article-title":"Personalized treatment with atypical antipsychotics","volume":"24","author":"Kim","year":"2007","journal-title":"Advances in Therapy"},{"key":"10.1016\/j.ridd.2008.10.010_bib97","doi-asserted-by":"crossref","first-page":"92","DOI":"10.4088\/JCP.v62n0204","article-title":"Long-term olanzapine treatment: Weight change and weight-related health factors in schizophrenia","volume":"62","author":"Kinon","year":"2001","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1016\/j.ridd.2008.10.010_bib98","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1136\/bmj.315.7116.1109","article-title":"Medicine based evidence: A prerequisite for evidence based medicine","volume":"315","author":"Knotterus","year":"1997","journal-title":"British Medical Journal"},{"key":"10.1016\/j.ridd.2008.10.010_bib99","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1592\/phco.23.6.735.32178","article-title":"Risperidone-associated diabetes mellitus: A pharmacovigilance study","volume":"23","author":"Koller","year":"2003","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ridd.2008.10.010_bib100","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1592\/phco.23.10.1123.32759","article-title":"Pancreatitis associated with antipsychotics: From the Food and Drug Administration's MedWatch Surveillance system and published reports","volume":"23","author":"Koller","year":"2003","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ridd.2008.10.010_bib101","doi-asserted-by":"crossref","first-page":"857","DOI":"10.4088\/JCP.v65n0619","article-title":"A survey of reports of quetiapine-associated hyperglycemia and diabetes mellitus","volume":"65","author":"Koller","year":"2004","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1016\/j.ridd.2008.10.010_bib102","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1097\/YCO.0b013e3282ab9941","article-title":"Co-morbidity of psychiatric disorder and medical illness in people with intellectual disabilities","volume":"20","author":"Kwok","year":"2007","journal-title":"Current Opinion in Psychiatry"},{"key":"10.1016\/j.ridd.2008.10.010_bib103","doi-asserted-by":"crossref","first-page":"421","DOI":"10.4088\/JCP.v67n0313","article-title":"Effect of mirtazapine treatment on body composition and metabolism","volume":"67","author":"Laimer","year":"2006","journal-title":"Journal of Clinical Psychiatry"},{"issue":"Suppl. 6","key":"10.1016\/j.ridd.2008.10.010_bib104","first-page":"10","article-title":"Switching antipsychotic therapy: What to expect and clinical strategies for improving therapeutic outcomes","volume":"68","author":"Lambert","year":"2007","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1016\/j.ridd.2008.10.010_bib105","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1111\/j.1532-5415.2005.53418.x","article-title":"Antipsychotic medications and drug-induced movement disorders other than parkinsonism: A population-based cohort study in older adults","volume":"53","author":"Lee","year":"2005","journal-title":"Journal of the American Geriatrics Society"},{"key":"10.1016\/j.ridd.2008.10.010_bib106","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/j.1600-0447.1999.tb00972.x","article-title":"A combined analysis of double-blind studies of risperidone vs. placebo and other antipsychotic agents: Factors associated with extrapyramidal symptoms","volume":"99","author":"Lemmens","year":"1999","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1016\/j.ridd.2008.10.010_bib107","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0920-9964(98)00105-4","article-title":"Efficacy and extrapyramidal side-effects of new antipsychotics olanzapine, quetiapine, risperidone, and sertrindole compared to conventional antipsychotics and placebo: A meta-analysis of randomized controlled trials","volume":"35","author":"Leucht","year":"1999","journal-title":"Schizophrenia Research"},{"key":"10.1016\/j.ridd.2008.10.010_bib108","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.ridd.2008.10.010_bib109","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1001\/archinte.165.22.2677","article-title":"Venous thromboembolism among elderly patients treated with atypical and conventional antipsychotic agents","volume":"165","author":"Liperoti","year":"2005","journal-title":"Archives of Internal Medicine"},{"key":"10.1016\/j.ridd.2008.10.010_bib110","first-page":"30","article-title":"Ethics and evidence-based medicine: Is there a conflict?","volume":"9","author":"Lowey","year":"2007","journal-title":"Medscape General Medicine"},{"key":"10.1016\/j.ridd.2008.10.010_bib111","first-page":"1471","article-title":"Recurrent priapism associated with use of aripiprazole","volume":"67","author":"Mago","year":"2006","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1016\/j.ridd.2008.10.010_bib112","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1176\/appi.ajp.161.8.1334","article-title":"Physical health monitoring of patients with schizophrenia","volume":"161","author":"Marder","year":"2004","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.ridd.2008.10.010_bib113","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1176\/jnp.2007.19.4.476","article-title":"Ziprasidone-induced catatonia symptoms [Letter]","volume":"19","author":"Markham-Abedi","year":"2007","journal-title":"Journal of Neuropsychiatry and Clinical Neurosciences"},{"key":"10.1016\/j.ridd.2008.10.010_bib114","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.2165\/00023210-200418140-00006","article-title":"Pharmacotherapy of pervasive developmental disorders in children and adolescents","volume":"18","author":"Masi","year":"2004","journal-title":"CNS Drugs"},{"key":"10.1016\/j.ridd.2008.10.010_bib115","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(08)60046-X","article-title":"Antipsychotic drugs for aggression in intellectual disability","volume":"371","author":"Matson","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.ridd.2008.10.010_bib116","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2165\/00003088-200746050-00001","article-title":"Clinical pharmacokinetics of atypical antipsychotics","volume":"46","author":"Mauri","year":"2007","journal-title":"Clinical Pharmacokinetics"},{"key":"10.1016\/j.ridd.2008.10.010_bib117","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3109\/10401239509149620","article-title":"A study of the clinical outcome of patients with profound mental retardation gradually withdrawn from chronic neuroleptic medication","volume":"7","author":"May","year":"1995","journal-title":"Annals of Clinical Psychiatry"},{"key":"10.1016\/j.ridd.2008.10.010_bib118","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1056\/NEJMoa013171","article-title":"Risperidone in children with autism and serious behavioral problems","volume":"347","author":"McCracken","year":"2002","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.ridd.2008.10.010_bib119","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1176\/appi.ajp.162.6.1142","article-title":"Risperidone for the core symptom domains of autism: Results from the study by the autism network of the research units on pediatric psychopharmacology","volume":"162","author":"McDougle","year":"2005","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.ridd.2008.10.010_bib120","doi-asserted-by":"crossref","first-page":"779","DOI":"10.2165\/00023210-200216110-00008","article-title":"Aripiprazole","volume":"16","author":"McGavin","year":"2002","journal-title":"CNS Drugs"},{"key":"10.1016\/j.ridd.2008.10.010_bib121","doi-asserted-by":"crossref","first-page":"444","DOI":"10.4088\/JCP.v66n0406","article-title":"Pregnancy outcome of women using atypical antipsychotic drugs: A prospective comparative study","volume":"66","author":"McKenna","year":"2005","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1016\/j.ridd.2008.10.010_bib122","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00213-004-1922-7","article-title":"Guidelines for prevention and treatment of adverse effects of antipsychotic drugs on glucose\u2013insulin homeostasis and lipid metabolism","volume":"175","author":"Melkersson","year":"2004","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.ridd.2008.10.010_bib123","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/PL00007539","article-title":"Prolactin-secreting pituitary adenoma in neuroleptic-treated patients with psychotic disorder","volume":"250","author":"Melkersson","year":"2000","journal-title":"European Archives of Psychiatry and Clinical Neurosciences"},{"key":"10.1016\/j.ridd.2008.10.010_bib124","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2004.01.014","article-title":"The effects of antipsychotic therapy on serum lipids: A comprehensive review","volume":"70","author":"Meyer","year":"2004","journal-title":"Schizophrenia Research"},{"key":"10.1016\/j.ridd.2008.10.010_bib125","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1002\/mds.20427","article-title":"Reversible withdrawal dyskinesia associated with quetiapine","volume":"20","author":"Michaelides","year":"2005","journal-title":"Movement Disorders"},{"issue":"8 Suppl. 7","key":"10.1016\/j.ridd.2008.10.010_bib126","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1017\/S1092852900002340","article-title":"Management of hyperprolactinemia in patients receiving antipsychotics","volume":"9","author":"Miller","year":"2004","journal-title":"CNS Spectrums"},{"key":"10.1016\/j.ridd.2008.10.010_bib127","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1176\/ajp.2007.164.4.630","article-title":"Adverse subjective experience with antipsychotics and its relationship to striatal and extrastriatal D2 receptors: A PET study in schizophrenia","volume":"164","author":"Mizrahi","year":"2007","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.ridd.2008.10.010_bib128","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1001\/archinte.167.16.1752","article-title":"Serious adverse drug events reported to the Food and Drug Administration, 1998\u20132003","volume":"167","author":"Moore","year":"2007","journal-title":"Archives of Internal Medicine"},{"key":"10.1016\/j.ridd.2008.10.010_bib129","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1080\/10401230500464737","article-title":"Focus on lower risk of tardive dyskinesia with atypical antipsychotics","volume":"18","author":"Nasrallah","year":"2006","journal-title":"Annals of Clinical Psychiatry"},{"issue":"Suppl. 13","key":"10.1016\/j.ridd.2008.10.010_bib130","first-page":"12","article-title":"Efficacy, safety and tolerability of quetiapine in patients with schizophrenia","volume":"63","author":"Nasrallah","year":"2002","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1016\/j.ridd.2008.10.010_bib131","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1097\/00004714-200008000-00016","article-title":"Case report of withdrawal syndrome after olanzapine discontinuation","volume":"20","author":"Nayudu","year":"2000","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"Suppl. 1","key":"10.1016\/j.ridd.2008.10.010_bib132","first-page":"20","article-title":"Metabolic consideration in the use of antipsychotic medications: A review of recent use","volume":"68","author":"Newcomer","year":"2007","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1016\/j.ridd.2008.10.010_bib133","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1177\/070674370605100803","article-title":"The metabolic effects of antipsychotic medications","volume":"51","author":"Newcomer","year":"2006","journal-title":"Canadian Journal of Psychiatry"},{"key":"10.1016\/j.ridd.2008.10.010_bib134","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1176\/appi.ajp.2007.06111886","article-title":"Atypical antipsychotic administration during late pregnancy: Placental passage and obstetrical outcomes","volume":"164","author":"Newport","year":"2007","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.ridd.2008.10.010_bib135","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/00007691-199902000-00013","article-title":"Olanzapine serum concentrations in psychiatric patients given standard doses: The influence of comedication","volume":"21","author":"Olesen","year":"1999","journal-title":"Therapeutic Drug Monitoring"},{"key":"10.1016\/j.ridd.2008.10.010_bib136","series-title":"Abilify","author":"Otsuka Pharmaceutical Company","year":"2007"},{"key":"10.1016\/j.ridd.2008.10.010_bib137","first-page":"155","article-title":"Pharmacologic treatment of autism","volume":"19","author":"Palermo","year":"2004","journal-title":"Journal of Child Neurology"},{"key":"10.1016\/j.ridd.2008.10.010_bib138","doi-asserted-by":"crossref","first-page":"513","DOI":"10.18553\/jmcp.2003.9.6.513","article-title":"Retrospective drug utilization review: Incidence of clinically relevant potential drug-drug interactions in a large ambulatory population","volume":"9","author":"Peng","year":"2003","journal-title":"Journal of Managed Care Pharmacy"},{"key":"10.1016\/j.ridd.2008.10.010_bib139","series-title":"GeodonR (ziprasidone HCl) GeodonR (ziprasidone mesylate) for injection for IM use only","author":"Pfizer","year":"2007"},{"key":"10.1016\/j.ridd.2008.10.010_bib140","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1176\/appi.ajp.161.9.1718","article-title":"Intranasal quetiapine abuse [Letter]","volume":"161","author":"Pierre","year":"2004","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.ridd.2008.10.010_bib141","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1176\/ajp.2007.164.1.174","article-title":"Quetiapine addiction? [Letter]","volume":"164","author":"Pinta","year":"2007","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.ridd.2008.10.010_bib142","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2165\/00002018-199819010-00005","article-title":"Managing antipsychotic-induced acute and tardive dystonia","volume":"19","author":"Raja","year":"1998","journal-title":"Drug Safety"},{"key":"10.1016\/j.ridd.2008.10.010_bib143","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1017\/S1461145701002620","article-title":"Novel antipsychotics and acute dystonic reactions","volume":"4","author":"Raja","year":"2001","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"10.1016\/j.ridd.2008.10.010_bib144","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1097\/SMJ.0b013e3180f62d53","article-title":"Additional evidence of the abuse potential of quetiapine","volume":"100","author":"Reeves","year":"2007","journal-title":"Southern Medical Journal"},{"key":"10.1016\/j.ridd.2008.10.010_bib145","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1176\/appi.ajp.162.7.1361","article-title":"Risperidone treatment of autistic disorder: Longer-term benefits and blinded discontinuation after 6 months","volume":"162","author":"Research Units on Pediatric Psychopharmacology Autism Network","year":"2005","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.ridd.2008.10.010_bib146","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1001\/archinte.165.16.1882","article-title":"Atypical antipsychotics and parkinsonism","volume":"165","author":"Rochon","year":"2005","journal-title":"Archives of Internal Medicine"},{"key":"10.1016\/j.ridd.2008.10.010_bib147","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/00004714-199908000-00020","article-title":"Possible interaction between warfarin and quetiapine","volume":"19","author":"Rogers","year":"1999","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1016\/j.ridd.2008.10.010_bib148","series-title":"Handbook of psychiatric drug therapy","author":"Rosenbaum","year":"2005"},{"key":"10.1016\/j.ridd.2008.10.010_bib149","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1176\/ajp.2006.163.12.2080","article-title":"Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia","volume":"163","author":"Rosenheck","year":"2006","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.ridd.2008.10.010_bib150","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.2337\/dc06-2001","article-title":"A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of topiramate controlled release in the treatment of obese type 2 diabetic patients","volume":"30","author":"Rosenstock","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ridd.2008.10.010_bib151","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ridd.2005.05.002","article-title":"Guidelines for the use of clozapine in individuals with developmental disabilities","volume":"27","author":"Sabaawi","year":"2006","journal-title":"Research in Developmental Disabilities"},{"key":"10.1016\/j.ridd.2008.10.010_bib152","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1177\/000486749202600208","article-title":"Drug-induced movement disorders in institutionalized adults with mental retardation: Clinical characteristics and risk factors","volume":"26","author":"Sachdev","year":"1992","journal-title":"Australian and New Zealand Journal of Psychiatry"},{"key":"10.1016\/j.ridd.2008.10.010_bib153","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1080\/j.1440-1614.2000.00737.x","article-title":"The current status of tardive dyskinesia","volume":"34","author":"Sachdev","year":"2000","journal-title":"Australian and New Zealand Journal of Psychiatry"},{"key":"10.1016\/j.ridd.2008.10.010_bib154","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1001\/archpsyc.64.10.1123","article-title":"A systematic review of mortality in schizophrenia: Is the differential mortality gap worsening over time?","volume":"64","author":"Saha","year":"2007","journal-title":"Archives of General Psychiatry"},{"key":"10.1016\/j.ridd.2008.10.010_bib155","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1176\/appi.psy.46.5.464","article-title":"An overview of psychotropic drug\u2013drug interactions","volume":"46","author":"Sandson","year":"2005","journal-title":"Psychosomatics"},{"key":"10.1016\/j.ridd.2008.10.010_bib156","unstructured":"Schneeweiss, S., Setoguchi, S., Brookhart, A., Dormuth, C., & Wang, P. S. (2007). Comparative safety of conventional and atypical antipsychotic medications: Risk of death in British Columbia seniors (Effective Health Care Research Report No. 2). Rockville, MD: Agency for Healthcare Research and Quality. Available at www.effectivehealthcare.ahrq.gov\/reports\/final.cfm."},{"key":"10.1016\/j.ridd.2008.10.010_bib157","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1177\/0269881106067765","article-title":"Aripiprazole use in individuals with intellectual disability and psychotic or behavioural disorders: A case series","volume":"20","author":"Shastri","year":"2006","journal-title":"Journal of Psychopharmacology"},{"key":"10.1016\/j.ridd.2008.10.010_bib158","unstructured":"Shekelle, P., Maglione, M., Bagley, S., Suttorp, M., Mojica, W. A., Carter, J., et al. (2007). Comparative effectiveness of off-label use of atypical antipsychotics (Comparative Effectiveness Review No. 6). Rockville, MD: Agency for Healthcare Research and Quality. January 2007. Available at: www.effectivehealthcare.ahrq.gov\/reports\/final.cfm."},{"key":"10.1016\/j.ridd.2008.10.010_bib159","doi-asserted-by":"crossref","first-page":"134","DOI":"10.4088\/PCC.v07n0312","article-title":"Ziprasidone and hypokalemia: A case of 2 predisposing factors for QTc prolongation without development of torsades de pointes","volume":"7","author":"Simpson","year":"2005","journal-title":"Primary Care Companion to the Journal of Clinical Psychiatry"},{"key":"10.1016\/j.ridd.2008.10.010_bib160","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S0010-440X(65)80028-1","article-title":"Withdrawal effects of phenothiazines","volume":"6","author":"Simpson","year":"1994","journal-title":"Comprehensive Psychiatry"},{"key":"10.1016\/j.ridd.2008.10.010_bib161","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ridd.2004.07.001","article-title":"The use of risperidone among individuals with mental retardation: Clinically supported or not?","volume":"26","author":"Singh","year":"2005","journal-title":"Research in Developmental Disabilities"},{"key":"10.1016\/j.ridd.2008.10.010_bib162","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1001\/jama.293.5.596","article-title":"Pharmacological treatment of neuropsychiatric symptoms of dementia: A review of the evidence","volume":"293","author":"Sink","year":"2005","journal-title":"Journal of the American Medical Association"},{"key":"10.1016\/j.ridd.2008.10.010_bib163","first-page":"221","article-title":"Thioridazine withdrawal-induced behavioral deterioration treated with clonidine: Two case reports","volume":"33","author":"Sovner","year":"1995","journal-title":"Mental Retardation"},{"key":"10.1016\/j.ridd.2008.10.010_bib164","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1742-7843.2007.00017.x","article-title":"Metabolic drug interactions with newer antipsychotics: A comparative review","volume":"100","author":"Spina","year":"2007","journal-title":"Basic & Clinical Pharmacology & Toxicology"},{"key":"10.1016\/j.ridd.2008.10.010_bib165","first-page":"328","article-title":"The Dyskinesia Identification System\u2013Coldwater (DIS\u2013Co): A tardive dyskinesia rating scale for the developmentally disabled","volume":"20","author":"Sprague","year":"1984","journal-title":"Psychopharmacology Bulletin"},{"key":"10.1016\/j.ridd.2008.10.010_bib166","doi-asserted-by":"crossref","first-page":"252","DOI":"10.4088\/JCP.v58n0603","article-title":"Clozapine withdrawal resulting in delirium with psychosis: A report of three cases","volume":"58","author":"Stanilla","year":"1997","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1016\/j.ridd.2008.10.010_bib167","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1185\/030079907X210633","article-title":"Practical prescribing with aripiprazole in schizophrenia: Consensus recommendations of a UK multidisciplinary panel","volume":"7","author":"Sullivan","year":"2007","journal-title":"Current Medical Research and Opinion"},{"key":"10.1016\/j.ridd.2008.10.010_bib168","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1097\/00131746-200611000-00003","article-title":"Strategies for maximizing clinical effectiveness in the treatment of schizophrenia","volume":"12","author":"Tandon","year":"2006","journal-title":"Journal of Psychiatric Practice"},{"key":"10.1016\/j.ridd.2008.10.010_bib169","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1176\/ajp.2007.164.2.350","article-title":"Black-market value of antipsychotics, antidepressants, and hypnotics in Las Vegas, Nevada [Letter]","volume":"164","author":"Tarasoff","year":"2007","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.ridd.2008.10.010_bib170","first-page":"538","article-title":"Drug utilization review: Mechanisms to improve its effectiveness and broaden its scope","volume":"40","author":"The U.S. Pharmacopeia Drug Utilization Review Advisory Panel","year":"2000","journal-title":"Journal of the American Pharmaceutical Association"},{"key":"10.1016\/j.ridd.2008.10.010_bib171","doi-asserted-by":"crossref","first-page":"602","DOI":"10.4088\/JCP.v61n0810e","article-title":"A possible case of quetiapine withdrawal syndrome","volume":"61","author":"Thurstone","year":"2000","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1016\/j.ridd.2008.10.010_bib172","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2165\/00002018-200528010-00003","article-title":"Atypical antipsychotics: From potassium channels to torsade de pointes and sudden death","volume":"28","author":"Titier","year":"2005","journal-title":"Drug Safety"},{"key":"10.1016\/j.ridd.2008.10.010_bib173","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1368-5031.2005.00498.x","article-title":"Aripiprazole in schizophrenia: Consensus guidelines","volume":"59","author":"Travis","year":"2005","journal-title":"International Journal of Clinical Practice"},{"key":"10.1016\/j.ridd.2008.10.010_bib174","doi-asserted-by":"crossref","first-page":"307","DOI":"10.2165\/00023210-200317050-00002","article-title":"Fatalities associated with therapeutic use and overdose of atypical antipsychotics","volume":"17","author":"Trenton","year":"2003","journal-title":"CNS Drugs"},{"key":"10.1016\/j.ridd.2008.10.010_bib175","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s002469910021","article-title":"Assessment of ventricular repolarization in deaf-mute children","volume":"21","author":"Tuncer","year":"2000","journal-title":"Pediatric Cardiology"},{"key":"10.1016\/j.ridd.2008.10.010_bib176","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0140-6736(08)60072-0","article-title":"Risperidone, haloperidol, and placebo in the treatment of aggressive challenging behaviour in patients with intellectual disability: A randomised controlled trial","volume":"371","author":"Tyrer","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.ridd.2008.10.010_bib177","first-page":"l3","article-title":"Behavioral toxicity of antipsychotic drugs","volume":"68","author":"Van Putten","year":"1987","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1016\/j.ridd.2008.10.010_bib178","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2165\/00024677-200302010-00003","article-title":"Hyperprolactinemia: Pathophysiology and management","volume":"2","author":"Verhelst","year":"2003","journal-title":"Treatments in Endocrinology"},{"issue":"Suppl. 3","key":"10.1016\/j.ridd.2008.10.010_bib179","first-page":"S648","article-title":"Absorption, metabolism and excretion of a single oral dose of 14C-paliperidone 1mg in healthy subjects","volume":"15","author":"Vermier","year":"2005","journal-title":"European Neuropsychopharmacology"},{"key":"10.1016\/j.ridd.2008.10.010_bib180","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1176\/ajp.2007.164.1.173a","article-title":"Intravenous quetiapine-cocaine use (\u201cQ-ball\u201d)","volume":"164","author":"Waters","year":"2007","journal-title":"American Journal of Psychiatry"},{"issue":"Suppl. 7","key":"10.1016\/j.ridd.2008.10.010_bib181","first-page":"1","article-title":"Roadmap Survey. Translating the psychopharmacology of antipsychotics to individualized treatment for severe mental illness: A roadmap","volume":"68","author":"Weiden","year":"2007","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1016\/j.ridd.2008.10.010_bib182","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/00007691-200108000-00015","article-title":"Fluvoxamine but not sertraline inhibits the metabolism of olanzapine: Evidence from a therapeutic drug monitoring service","volume":"23","author":"Weigmann","year":"2001","journal-title":"Therapeutic Drug Monitoring"},{"key":"10.1016\/j.ridd.2008.10.010_bib183","first-page":"545","article-title":"Risperidone use in the treatment of behavioral symptoms in children with autism","volume":"32","author":"West","year":"2006","journal-title":"Pediatric Nursing"},{"key":"10.1016\/j.ridd.2008.10.010_bib184","doi-asserted-by":"crossref","first-page":"399","DOI":"10.3122\/jabfm.2007.04.060210","article-title":"Screening tests for adults with intellectual disabilities","volume":"20","author":"Wilkinson","year":"2007","journal-title":"Journal of the American Board of Family Medicine"},{"key":"10.1016\/j.ridd.2008.10.010_bib185","doi-asserted-by":"crossref","first-page":"282","DOI":"10.4088\/JCP.v62n0411","article-title":"Optimal dosing with risperidone: Updated recommendations","volume":"62","author":"Williams","year":"2001","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1016\/j.ridd.2008.10.010_bib186","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1037\/1064-1297.9.3.285","article-title":"Risk factors for tardive dyskinesia in a large population of youths and adults","volume":"9","author":"Wszola","year":"2001","journal-title":"Experimental and Clinical Psychopharmacology"},{"key":"10.1016\/j.ridd.2008.10.010_bib187","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1176\/ajp.2006.163.12.2064","article-title":"Atypical antipsychotics in the treatment of schizophrenia during pregnancy and the postpartum","volume":"163","author":"Yaeger","year":"2006","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.ridd.2008.10.010_bib188","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1212\/01.wnl.0000218214.64942.64","article-title":"Andersen\u2013Tawil syndrome: Definition of a neurocognitive phenotype","volume":"66","author":"Yoon","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.ridd.2008.10.010_bib189","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0022-3956(03)00018-9","article-title":"Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients","volume":"37","author":"Zimmermann","year":"2003","journal-title":"Journal of Psychiatric Research"}],"container-title":["Research in Developmental Disabilities"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891422208001248?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891422208001248?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T22:08:33Z","timestamp":1684793313000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0891422208001248"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7]]},"references-count":189,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,7]]}},"alternative-id":["S0891422208001248"],"URL":"https:\/\/doi.org\/10.1016\/j.ridd.2008.10.010","relation":{},"ISSN":["0891-4222"],"issn-type":[{"value":"0891-4222","type":"print"}],"subject":[],"published":{"date-parts":[[2009,7]]}}}